HRP20110453T1 - Sastav peleta lipoične kiseline - Google Patents
Sastav peleta lipoične kiseline Download PDFInfo
- Publication number
- HRP20110453T1 HRP20110453T1 HR20110453T HRP20110453T HRP20110453T1 HR P20110453 T1 HRP20110453 T1 HR P20110453T1 HR 20110453 T HR20110453 T HR 20110453T HR P20110453 T HRP20110453 T HR P20110453T HR P20110453 T1 HRP20110453 T1 HR P20110453T1
- Authority
- HR
- Croatia
- Prior art keywords
- composition according
- lipophilic medium
- lipoic acid
- lipophilic
- active substance
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 26
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 title claims abstract 5
- 235000019136 lipoic acid Nutrition 0.000 title claims abstract 5
- 229960002663 thioctic acid Drugs 0.000 title claims abstract 5
- 239000008188 pellet Substances 0.000 title claims abstract 3
- 239000013543 active substance Substances 0.000 claims 5
- 239000003026 cod liver oil Substances 0.000 claims 4
- 235000012716 cod liver oil Nutrition 0.000 claims 4
- 235000021323 fish oil Nutrition 0.000 claims 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims 2
- 229960002733 gamolenic acid Drugs 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 claims 1
- 229960002873 benfotiamine Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 239000007903 gelatin capsule Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960001786 megestrol Drugs 0.000 claims 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Sastav koji sadrži pelete lipoične kiseline, ili jednu od njezinih soli, naznačen time, da jest u barem jednom lipofilnom mediju. Patent sadrži još 22 patentna zahtjeva.
Claims (23)
1. Sastav koji sadrži pelete lipoične kiseline, ili jednu od njezinih soli, naznačen time, da jest u barem jednom lipofilnom mediju.
2. Sastav prema patentnom zahtjevu 1, naznačen time, da navedeni lipofilni medij jest farmaceutski prihvatljiva i/ili jestiva lipofilna komponenta, koja je inertna ili ima blagotvorna svojstva na ljudski ili životinjski organizam.
3. Sastav prema patentnom zahtjevu 2, naznačen time, da navedeni lipofilni medij ima antioksidativna svojstva.
4. Sastav prema patentnim zahtjevima od 1 do 3, naznačen time, da navedeni lipofilni medij sadrži EPA i DHA.
5. Sastav prema patentnim zahtjevima od 1 do 3, naznačen time, da se navedeni lipofilni medij odabire između ribljeg ulja ili ulja jetre bakalara.
6. Sastav prema patentnom zahtjevu 5, naznačen time, da se navedeni lipofilni medij odabire između ribljeg ulja ili ulja jetre bakalara u pročišćenom obliku i obogaćenom u odnosu na Omega 3.
7. Sastav prema patentnom zahtjevu 6, naznačen time, da se navedeni lipofilni medij odabire između ribljeg ulja i ulja jetre bakalara u pročišćenom obliku i obogaćenom u odnosu na EPA i DHA.
8. Sastav prema patentnim zahtjevima od 1 do 7, naznačen time, da navedeni lipofilni medij sadrži gama-linolensku kiselinu.
9. Sastav prema patentnim zahtjevima 1 ili 2, naznačen time, da sadrži i druge aktivne tvari.
10. Sastav prema patentnim zahtjevima od 1 do 9, naznačen time, da sadrži i benfotiamin.
11. Sastav prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da je u obliku jedinica doziranja.
12. Sastav prema patentnom zahtjevu 11, naznačen time, da je u obliku želatinskih kapsula.
13. Sastav prema bilo kojem od patentnih zahtjeva 11 ili 12, naznačen time, da sadrži od 10 do 1000 mg lipoične kiseline.
14. Sastav prema patentnom zahtjevu 13, naznačen time, da sadrži od 100 do 800 mg lipoične kiseline.
15. Sastav prema bilo kojem od patentnih zahtjeva od 11 do 14, naznačen time, da sadrži između 100 i 1000 mg ribljeg ulja ili ulja jetre bakalara u pročišćenom obliku.
16. Sastav prema bilo kojem od patentnih zahtjeva od 10 do 13, naznačen time, da sadrži između 100 i 3000 mg smjese EPA i DHA.
17. Sastav prema bilo kojem od patentnih zahtjeva od 11 do 14, naznačen time, da sadrži 300 do 1000 mg gama-linolenske kiseline.
18. Sastav prema bilo kojem od patentnih zahtjeva od 1 do 17, naznačen time, da sadrži i aktivnu tvar odabranu između gabapentina, pregabalina, olmesartan kaptoprila, interferona, akamprosata i megestrola.
19. Sastav prema bilo kojem od patentnih zahtjeva od 1 do 17, naznačen time, da sadrži i aktivnu tvar s antioksidativnim djelovanjem.
20. Uporaba sastava prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, da jest za pripremu lijeka za liječenje oksidativnog stresa.
21. Jedinica doziranja, naznačena time, da sadrži sastav prema bilo kojem od patentnih zahtjeva od 1 do 19.
22. Sastav prema patentnom zahtjevu 9, naznačen time, da navedena druga aktivna tvar jest antagonist angiotenzina II.
23. Sastav prema patentnom zahtjevu 9, naznačen time, da navedena druga aktivna tvar jest ACE inhibitor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002051A ITMI20072051A1 (it) | 2007-10-23 | 2007-10-23 | Composizione a base di pellet di acido lipoico |
| PCT/IB2008/002835 WO2009053824A1 (en) | 2007-10-23 | 2008-10-23 | Lipoic acid pellet composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110453T1 true HRP20110453T1 (hr) | 2011-07-31 |
Family
ID=40313864
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110453T HRP20110453T1 (hr) | 2007-10-23 | 2011-06-16 | Sastav peleta lipoične kiseline |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US9820948B2 (hr) |
| EP (1) | EP2217220B1 (hr) |
| JP (1) | JP5626890B2 (hr) |
| KR (1) | KR101599078B1 (hr) |
| CN (1) | CN101861144B (hr) |
| AT (1) | ATE506053T1 (hr) |
| AU (1) | AU2008315667B2 (hr) |
| BR (1) | BRPI0816587A2 (hr) |
| CA (1) | CA2703152C (hr) |
| CY (1) | CY1112122T1 (hr) |
| DE (1) | DE602008006454D1 (hr) |
| DK (1) | DK2217220T3 (hr) |
| ES (1) | ES2363880T3 (hr) |
| HR (1) | HRP20110453T1 (hr) |
| IL (1) | IL205211A (hr) |
| IT (1) | ITMI20072051A1 (hr) |
| MX (1) | MX2010004481A (hr) |
| NZ (1) | NZ584884A (hr) |
| PL (1) | PL2217220T3 (hr) |
| PT (1) | PT2217220E (hr) |
| RS (1) | RS51712B (hr) |
| RU (1) | RU2501558C2 (hr) |
| SI (1) | SI2217220T1 (hr) |
| TN (1) | TN2010000163A1 (hr) |
| UA (1) | UA100394C2 (hr) |
| WO (1) | WO2009053824A1 (hr) |
| ZA (1) | ZA201002777B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0818473D0 (en) | 2008-10-08 | 2008-11-12 | Probio Nutraceuticals As | Composition |
| WO2011099031A1 (en) | 2010-02-11 | 2011-08-18 | Zota Health Care Limited | Active antioxidants for all age group |
| GB201006200D0 (en) * | 2010-04-14 | 2010-06-02 | Ayanda As | Composition |
| US20130045273A1 (en) * | 2011-08-19 | 2013-02-21 | John Cuomo | Methods for using nutritional supplements containing lipoic acids and sulfur containing compounds |
| CA2965671A1 (en) * | 2014-10-24 | 2016-04-28 | Robert Shorr | Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome |
| MX2016017321A (es) * | 2016-12-14 | 2018-08-20 | Cidat S A De C V | Combinacicones y metodos para el tratamiento de dolor neuropatico. |
| CN106729725A (zh) * | 2017-03-21 | 2017-05-31 | 北京百慧生化制药有限责任公司 | 硫辛酸作为抗氧化剂在多烯酸乙酯制剂或蛹油α‑亚麻酸乙酯制剂中的应用 |
| IT202200007232A1 (it) * | 2022-04-12 | 2023-10-12 | Uriach Italy S R L | Composizione comprendente acido lipoico, vitamina d e glutatione, suoi usi, e relative composizioni farmaceutiche e nutraceutiche |
| WO2023199241A1 (en) * | 2022-04-12 | 2023-10-19 | URIACH ITALY S.r.l. | Composition comprising lipoic acid, vitamin d and glutathione, uses thereof, and pharmaceutical and nutraceutical compositions thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0774166B2 (ja) * | 1987-02-06 | 1995-08-09 | 信越化学工業株式会社 | 徐放性被覆薬剤の製造方法 |
| US6197340B1 (en) * | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
| WO2001021208A1 (en) * | 1999-09-23 | 2001-03-29 | Juvenon Corporation | Nutritional supplement for increased energy and stamina |
| WO2002036202A2 (en) * | 2000-11-02 | 2002-05-10 | Nutrition 21, Inc. | Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid |
| ITMI20012732A1 (it) * | 2001-12-20 | 2003-06-20 | Health Pharma S R L | Integratore alimentare per neuropatici |
| US20060193789A1 (en) * | 2002-10-25 | 2006-08-31 | Foamix Ltd. | Film forming foamable composition |
| CN1694695A (zh) * | 2002-11-07 | 2005-11-09 | 帝斯曼知识产权资产管理有限公司 | 包含表没食子儿茶素没食子酸酯的新颖的营养药物性组合物 |
| US7387793B2 (en) * | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| US20050181047A1 (en) * | 2004-02-18 | 2005-08-18 | Jaime Romero | Compositions and methods for timed release of water-soluble nutritional supplements |
| US20060182729A1 (en) * | 2005-02-17 | 2006-08-17 | Prasad Kedar N | Combat/training antioxidant micronutrient formulation and method of administration |
| JP2006298831A (ja) * | 2005-04-21 | 2006-11-02 | Sumitomo Shoji Chemicals Co Ltd | αリポ酸粉体被覆物及びその製造方法、並びにαリポ酸含有食品 |
| JP5157001B2 (ja) * | 2005-04-30 | 2013-03-06 | ビーエイチエヌ株式会社 | 安定化α−リポ酸組成物及びその利用 |
| US20060270625A1 (en) * | 2005-05-13 | 2006-11-30 | Eastern Virginia Medical School | Nutraceuticals for the treatment of neuropathy |
| JP5085329B2 (ja) * | 2005-09-12 | 2012-11-28 | 協和発酵バイオ株式会社 | α−リポ酸含有組成物 |
| CN101394842B (zh) * | 2006-04-26 | 2011-09-21 | Dpi溶液株式会社 | 在水相中稳定的α硫辛酸胶囊组合物及制备该组合物的方法 |
| ITMI20061024A1 (it) * | 2006-05-25 | 2007-11-26 | Eurand Pharmaceuticals Ltd | Pellet a base di acido lipoico |
-
2007
- 2007-10-23 IT IT002051A patent/ITMI20072051A1/it unknown
-
2008
- 2008-10-23 BR BRPI0816587-4A2A patent/BRPI0816587A2/pt not_active IP Right Cessation
- 2008-10-23 DK DK08840866.1T patent/DK2217220T3/da active
- 2008-10-23 RS RS20110249A patent/RS51712B/en unknown
- 2008-10-23 KR KR1020107010844A patent/KR101599078B1/ko not_active IP Right Cessation
- 2008-10-23 US US12/739,449 patent/US9820948B2/en not_active Expired - Fee Related
- 2008-10-23 PT PT08840866T patent/PT2217220E/pt unknown
- 2008-10-23 MX MX2010004481A patent/MX2010004481A/es active IP Right Grant
- 2008-10-23 CN CN2008801173655A patent/CN101861144B/zh not_active Expired - Fee Related
- 2008-10-23 SI SI200830241T patent/SI2217220T1/sl unknown
- 2008-10-23 JP JP2010530581A patent/JP5626890B2/ja not_active Expired - Fee Related
- 2008-10-23 NZ NZ584884A patent/NZ584884A/en not_active IP Right Cessation
- 2008-10-23 PL PL08840866T patent/PL2217220T3/pl unknown
- 2008-10-23 WO PCT/IB2008/002835 patent/WO2009053824A1/en active Application Filing
- 2008-10-23 AT AT08840866T patent/ATE506053T1/de active
- 2008-10-23 ES ES08840866T patent/ES2363880T3/es active Active
- 2008-10-23 UA UAA201006077A patent/UA100394C2/ru unknown
- 2008-10-23 CA CA2703152A patent/CA2703152C/en not_active Expired - Fee Related
- 2008-10-23 AU AU2008315667A patent/AU2008315667B2/en not_active Ceased
- 2008-10-23 DE DE602008006454T patent/DE602008006454D1/de active Active
- 2008-10-23 RU RU2010120706/15A patent/RU2501558C2/ru not_active IP Right Cessation
- 2008-10-23 EP EP08840866A patent/EP2217220B1/en active Active
-
2010
- 2010-04-15 TN TN2010000163A patent/TN2010000163A1/fr unknown
- 2010-04-20 ZA ZA2010/02777A patent/ZA201002777B/en unknown
- 2010-04-21 IL IL205211A patent/IL205211A/en not_active IP Right Cessation
-
2011
- 2011-06-16 HR HR20110453T patent/HRP20110453T1/hr unknown
- 2011-07-11 CY CY20111100670T patent/CY1112122T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110453T1 (hr) | Sastav peleta lipoične kiseline | |
| JP5069448B2 (ja) | 脳卒中再発予防用組成物 | |
| Chung et al. | Fish Oil Supplementation of Control and (n-3) Fatty Acid-Deficient Male Rats Enhances Reference and Working Memory Performance and Increases Brain Regional Docosahexaenoic Acid Levels3 | |
| RU2012114832A (ru) | Питательные композиции для модулирования воспаления, содержащие экзогенный витамин к2 | |
| Kundam et al. | Bioactive compounds in fish and their health benefits | |
| BRPI0516718A (pt) | forma de dosagem de ibuprofeno de liberação modificada | |
| CA2705936C (en) | Use of omega-3-fatty acids for pain relief | |
| NZ600167A (en) | Concentrated therapeutic phospholipid compositions | |
| HRP20171431T1 (hr) | Terapijska parenteralna primjena krilovog ulja | |
| RU2013146517A (ru) | Композиции и способы, пригодные для облегчения возрастных заболеваний | |
| KR20080094073A (ko) | 뇌졸중 재발 예방용 조성물 | |
| NZ591810A (en) | Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid | |
| UA102478C2 (en) | Capsule composition | |
| Adameova et al. | Anti-atherosclerotic molecules targeting oxidative stress and inflammation | |
| JP2016053065A5 (hr) | ||
| EA200970374A1 (ru) | Лечение антиаритмическими средствами и омега-3 жирными кислотами и их комбинированным продуктом | |
| JP2014507411A (ja) | 骨及び関節の成長、回復、及び維持の促進のための食事サプリメント | |
| RU2008103281A (ru) | Способы и композиции для профилактики и лечения воспалительного заболевания | |
| RU2009115791A (ru) | Смесь солей железа и меди, маскирующая металлический вкус | |
| ATE443515T1 (de) | Omega-3-fettsäuren und omega-6-fettsäuren enthaltende zusammensetzung | |
| HRP20160406T1 (hr) | Postupci i pripravci za liječenje sa štitnjačom povezanih medicinskih stanja sa sniženiim folatima | |
| HRP20201221T1 (hr) | Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu | |
| JP4005104B2 (ja) | 脳卒中再発予防用組成物 | |
| WO2006080086A1 (ja) | 中枢神経系の疲労回復又は疲労予防のための組成物 | |
| Stewart et al. | Polyunsaturated fatty acid supplementation in MS |